M model with personal parametric adjustments was performed on the NBM-
M model with personal parametric adjustments was performed on the NBM-100 readings, for a total of 80 data points. The calibration phase lasted 1.5?.5 hours. The reference BG range was 64?47 mg/dl. The resulting median relative absolute error was 11.5 , and the median absolute error was 18 mg/dl. A Clarke error grid analysis showed that 100 of the measurements fell within zones A (79 ) and B (21 ). In all these clinical settings there was good patient compliance and no adverse effects were identified. One of the trials did not meet a self-consistency criterion for the calibration, and was excluded. Conclusion This study indicates the potential use of the noninvasive NBM-100 as a device for continual, accurate, safe, and easy-to-use BG evaluation for ICU. Consequently, it will improve patient care and survival, as well as reducing staff workload. It has the promise for trend analysis, hypoglycemia detection and closedloop systems enabling automatic glycemic control.Conclusion Our data indicate that ISF is a promising site for CGM in critically ill patients. An implementation of this approach is microdialysis in combination with a glucose sensor. However, systems still have to be improved to be suitable for routine care in the ICU.P256 Does implementation of a computerised, decisionsupported intensive insulin protocol achieve tight glycaemic control? A prospective observational studyR Shulman1, R Greene2, P Glynne1 1University College Hospital, London, UK; 1King’s College, London, UK Critical Care 2006, 10(Suppl 1):P256 (doi: 10.1186/cc4603) Introduction Implementation of an intensive insulin protocol, aiming for tight glycaemic control (TGC) (BG 4.4?.1 mmol/l), has resulted in a significant mortality reduction from 8 with conventional treatment to 4.6 in the TGC group [1]. An observational study suggests that a less stringent target BG range of 4? mmol/l may achieve mortality benefits [2]. Objective To determine the degree to which TGC can be maintained using a TGC protocol.P255 Evaluation of a noninvasive blood glucose ABT-737 price monitoring device for critically ill patientsA Kononenko1, D Dvir2, B Grunberg2, J Cohen2, E Gabis1, P Singer2 1Orsense LTD, Nes-Ziona, Israel; 2Rabin Medical Center, Petah-Tikva, Israel Critical Care 2006, 10(Suppl 1):P255 (doi: 10.1186/cc4602) Introduction Critically ill patients frequently experience abnormalities in carbohydrate metabolism and a severe insulin resistance state. Hyperglycemia is a negative predictor of outcome in these patients, as high blood glucose (BG) values are associated with an increased risk of morbidity and mortality. Currently, BG monitoring methods cannot fulfill the need for continuous glucose monitoring in order to safely implement tight glucose control protocols. The purpose of this study is to evaluate the feasibility of the NBM-100 device (OrSense Ltd) for non-invasive (NI) continuous glucose monitoring in critically ill patients. Materials and methods The NBM-100 uses a finger-based sensor shaped as a ring, located at the finger’s base. Red/nearinfrared occlusion spectroscopy detects and analyzes BG and hemoglobin concentrations. The NBM-100 utilizes an enhanced optical signal resulting from a temporary PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27362935 over-systolic occlusion, produced by a finger-based pneumatic cuff. The resulting changes in the optical signal create the sensitivity needed for measuring the PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28549975 glucose concentrations non-invasively. A study was conducted on six patients (three female, three male, ages 44?8 years) in.